Evidence mapPaperPMID 8269798Full record

Trial reportDiabetes care1993

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

D Giugliano, N De Rosa, G Di Maro, R Marfella, R Acampora, R Buoninconti, F D'Onofrio

Registry-linked trialAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes care, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04626089 (Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04626089 phase2withdrawnstarted 2021, after this paper: background citation

Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.

Ran2021Enrolled0Registered outcomes12Posted comparisons0ConditionsMetabolic Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Type 2 DiabetesArmsMetformin glycinate, Placebo Oral Tablet
Open the trial in the graph
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Fibrinolytic activity in Nigerian diabetics.Postgraduate medical journal · 2004
    Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Article
  17. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.Molecular cancer research : MCR · 2019
    Article
  18. Article
  19. Efficacy of metformin in the management of periodontitis: A systematic review and meta-analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

D GiuglianoDepartment of Gerontology and Metabolic Diseases, Second University of Naples, Italy.
N De Rosa
G Di Maro
R Marfella
R Acampora
R Buoninconti
F D'Onofrio
University of Campania "Luigi Vanvitelli" · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the effects of metformin on blood pressure, left ventricular mass, and some metabolic and endocrine parameters in nondiabetic, obese, hypertensive women. RESEARCH DESIGN AND

methodsTwelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. All patients were hospitalized 4 times, i.e., before randomization and after each treatment (metformin or placebo), to conduct metabolic and cardiovascular investigations (oral glucose tolerance test, euglycemic clamp associated with indirect calorimetry, and echocardiography).

resultsFasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin.

conclusionsThese findings suggest that metformin treatment in obese, nondiabetic, hypertensive women produces a more favorable cardiovascular risk profile.

Indexed as

Blood GlucoseBlood PressureCalorimetryCholesterolDouble-Blind MethodEchocardiographyFemaleFibrinogenGlucose Clamp TechniqueGlucose Tolerance TestGlycated HemoglobinHumansHypertensionInsulinMetforminMiddle AgedBlood GlucoseCholesterolFibrinogenGlycated HemoglobinInsulinMetforminTriglycerides

Identifiers

PMID8269798
OpenAlexW2039851346

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.